

SYNTHESIS OF 2-(8-BROMONAPHTHO[2,1-*B*]FURAN-2-YL)-5-ARYL-1,3,4-OXADIAZOLES AS POTENTIAL ANTIMICROBIAL AGENTS

D. Ramesh², VP. Vaidya^{1*}, MN. Kumaraswamy² and C. Chandrashekhar³

¹Department of PG Studies and Research in Chemistry, Kuvempu University, Shankaraghatta -577 451, Karnataka, India.

²Department of PG Studies in Chemistry, Sir. M.V. Government Science College, Bhadravathi-577302, Karnataka, India.

³Department of PG Studies in Medicinal Chemistry, SDM College, Ujjire-574240. Dakshina Kannada, Karnataka, India.

ABSTRACT

The reaction of ethyl 8-bromonaphtho[2,1-*b*]furan-2-carboxylate **2** obtained by the bromination of ethyl naphtho[2,1-*b*]furan-2-carboxylate **1** with hydrazine hydrate, afforded 8-bromonaphtho[2,1-*b*]furan-2-carboxyhydrazide **3** which served as an excellent intermediate for the synthesis of title compounds. These were obtained by two different routes from hydrazide **3**. The first route involved the conversion of hydrazide **3** into *N*-aryl 8-bromonaphtho[2,1-*b*]furan-2-carbohydrazides **4(a-f)**, which underwent smooth cyclization on treatment with phosphorus oxychloride to furnish 2-(8-bromonaphtho[2,1-*b*]furan-2-yl)-5-aryl-1,3,4-oxadiazoles **5(a-k)**. In the second methodology the oxadiazoles **5(a-k)** were obtained by converting hydrazide **3** into corresponding Schiff bases **6(a-k)** followed by ring closure using bromine in acetic acid in presence of anhydrous sodium acetate. The structures of newly synthesized compounds have been established by analytical and spectral studies. All the compounds in the series have been screened for their antibacterial and antifungal activities.

Keywords: Naphtho[2,1-*b*]furo-1,3,4-oxadiazoles, antibacterial activity, antifungal activity.

INTRODUCTION

Among the wide variety of heterocycles that have been explored for developing pharmaceutically important molecules, 1,3,4-oxadiazole derivatives have played a vital role in the medicinal chemistry. There are large number of synthetic compounds, encompassing oxadiazole nucleus, used as antibacterial¹⁻⁵, antifungal⁶⁻⁷, anticonvulsant⁸, anti-inflammatory⁹⁻¹⁰ and anticancer¹¹ agents, when properly substituted in 2 and 5 positions.

The biheterocyclic compounds having 2-arylamino-1,3,4-oxadiazoles, obtained from oxidative cyclization of corresponding thiosemicarbazides have been shown to exhibit a broad spectrum of biological activities¹²⁻¹⁴. Some

of naphtho[2,1-*b*]furo-1,3,4-oxadiazoles, synthesized in our laboratory, have been screened for antimicrobial activity and have been found to possess considerable antibacterial as well as antifungal activities¹⁵⁻¹⁶. The literature survey revealed that the replacement of one or more hydrogen atom by the corresponding number of halogen atom enhanced the biological profile of heterocyclic compounds by many folds¹⁷. Thus some of the biheterocyclic compounds having bromine atom at C-8 of naphthofuran moiety have been reported to exhibit considerable antibacterial activity¹⁸. Similarly bromosubstituted naphthofuran compounds exhibit muscarinic antagonist activity¹⁹. Further, introduction of a bromine atom provides more

routes for synthetic variation in the molecule under study and to synthesize pharmacologically interesting compounds compared to their non brominated analogues.

Encouraged by the wide spectrum of biological activities associated with biheterocyclic compounds containing naphtho[2,1-*b*]furan & 1,3,4-oxadiazole moieties and bromine bearing compounds and in continuation of our earlier work²⁰⁻²⁶, we report in this paper the synthesis of title compounds by different routes and investigation of their biological activity.

MATERIALS AND METHOD

Melting points were determined by an open capillary method and are uncorrected. The IR spectra (in KBr pellets) were recorded on Shimadzu FTIR spectrum 8000 Spectrometer. The NMR spectra (¹H and ¹³C) were recorded on Bruker-400 MHz Spectrometer, using CDCl₃ and DMSO-d₆ as solvent and TMS as internal standard reference. Chemical shifts are expressed as δ values [in ppm]. The mass spectra were recorded on Bruker Apex-II mass Spectrophotometer and Shimadzu LC-MS Instrument. Purity of compounds was checked by thin layer chromatography (TLC) on a silica gel plate and visualizing the spots under iodine vapour.

EXPERIMENTAL

Synthesis of ethyl 8-bromonaphtho[2,1-*b*]furan-2-carboxylate 2

To a solution of ethyl naphtho[2,1-*b*]furan-2-carboxylate 1 (2.4 g, 0.01 mol) in glacial acetic acid (50 ml), bromine (0.8 g, 0.01 mol) in glacial acetic acid (20 ml) was slowly added with stirring over a period of 1 h at a temperature of 0-5°C and the stirring was continued for 3 h. The reaction mixture was poured into ice-cold water and the solid obtained was filtered out. It was washed with water, dried and the product was recrystallized from ethanol.

Synthesis of 8-bromonaphtho[2,1-*b*]furan-2-carbohydrazide 3

An aqueous solution of hydrazine hydrate (15 ml, 99%) was added to a solution of ethyl 8-bromonaphtho[2,1-*b*]furan-2-carboxylate 2 (3.2g, 0.01 mol) in ethanol (30 ml). The reaction mixture was heated under reflux for 2 h and cooled to room temp. The hydrazide 3 that separated, as a solid, was collected and recrystallized from ethanol.

Synthesis of N- (aroyl-8-bromonaphtho[2,1-*b*]furan-2-carbohydrazides 4a-f

A mixture of compound 3 (3.05 g, 0.01 mol) and benzoyl chloride (1.4 g, 0.01 mol) was stirred at room temperature, followed by drop wise addition of aqueous sodium hydroxide (5 ml, 0.01 N), stirring was continued for further period of 1 h. The mixture was then poured into water, the product 4d, thus obtained as solid was filtered, dried and recrystallized from ethanol.

Other compounds 4a-c, e-f in the series were prepared similarly by using appropriately substituted benzoyl chlorides.

Synthesis of N-(arylmethylene)-8-bromonaphtho[2,1-*b*]furan-2-carbohydrazides (Schiff's base) 6a-k

To a solution of naphtho[2,1-*b*]furan-2-carbohydrazide 3 (3.05 g, 0.01 mol) in dioxane (15 ml), 4-methoxybenzaldehyde (1.36 g, 0.01 mol) was added. The reaction mixture was kept for reflux on water bath for 2 h. Then it was poured in to ice-cold water to get the product 6a and the solid separated out was filtered and dried. The product was recrystallized from dioxane.

The compounds 6b-k were synthesized similarly by using appropriate aldehydes.

Synthesis of 2-(8-bromonaphtho[2,1-*b*]furan-2-yl)-5-aryl-1,3,4-oxadiazoles 5a-f

Method-A

The compound 4d (3.3 g, 0.01 mol) was refluxed with phosphorous oxychloride (15 ml) for 3 h. cooled and poured into crushed ice with stirring. The solid thus separated was filtered and recrystallized from methanol.

The compounds 5a-c, and 5e-f were prepared by adopting same procedure from 4a-c, and 4e-f.

Method-B

Compounds 6d (3.93 g, 0.01 mol) and anhydrous sodium acetate (0.15 g) were mixed and suspended in glacial acetic acid (5 ml). Bromine (1 g) in glacial acetic acid (0.25 ml) was added to the above mixture with stirring. After a few minutes the mixture became warm and the colour of bromine faded. The mixture was stirred for a further period of 30 min. then decomposed in ice-cold water (100 ml). The product 5d was collected and recrystallized from ethanol.

The compounds 5a-c, and 5e-f were prepared by adopting same procedure from 6a-c, and 6e-f.

The physical data of newly synthesized compounds are tabulated in Table - 1.

Evaluation of Biological activities

The compounds encompassing naphthofuran, and oxadiazoles are known to exhibit wide spectrum of biological activities. Hence, it was contemplated to evaluate newly synthesized compounds for antimicrobial activities by adopting literature procedure.

Antimicrobial activity

The newly synthesized compounds were screened for their antibacterial activity against *Bacillus subtilis*, *Pseudomonas aeruginosa* *Staphylococcus pyogenes*, *Staphylococcus aureus* and antifungal activity against *Aspergillus niger*, *Aspergillus flavus*, *Candida albicans* according to cup plate method²⁸ at a concentration of 0.005 mol/ml against all the organisms. Chloramphenicol and Fluconazole were used as standard drugs for antibacterial and antifungal activity respectively. The zone of inhibition was compared with the standard drug after 24 h of incubation at 25° C for antibacterial activity and after 48 h at 30° C for antifungal activity. The results of such studies are given in Table 2.

RESULT AND DISCUSSION

The starting material required for the present investigation, ethyl naphtho[2,1-*b*]furan-2 carboxylate **1**, was synthesized by a reported method from our laboratory²¹. Bromination of ester **1** afforded ethyl 8-bromonaphtho[2,1-*b*]furan-2-carboxylate **2** structure of which was established by spectral studies. The IR (KBr) spectrum exhibited absorption band at 1720 cm⁻¹ due to ester carbonyl group. The 300 MHz ¹H NMR (DMSO-d₆) spectrum of **2** showed the signal at δ 1.46 triplet (3H) (J=7.12 Hz) and δ 4.48 quartet (2H) (J=7.11) indicating the presence of an ethyl group of ester and δ 7.2-8.5 multiplet (6H) for aromatic protons. The ¹H NMR was conspicuous by the absence of signal at δ 8.6, which was present in its precursor **1** due to the proton at C-8, confirming the bromination at C-8 of naphthofuran moiety. The mass spectrum showed the molecular ion peak at m/z 319 (M⁺) and 321(M+2) corresponding to its molecular weight. The key intermediate 8-bromonaphtho[2,1-*b*]furan-2-carboxyhydrazide **3** was obtained by the condensation of **2** with hydrazine hydrate (99%) in presence of catalytic amount of concentrated hydrochloric acid in ethanol at reflux temperature. The IR spectrum of **3** exhibited characteristic bands at 3100 cm⁻¹ and 3123 cm⁻¹ due to -NH and -NH₂ absorption and 1656 cm⁻¹ due to carbonyl group. In ¹H NMR

spectrum D₂O exchangeable broad singlet (2H) at δ 4.15, multiplet (6H) at δ 7.6-8.4 and another singlet (1H) D₂O exchangeable at δ 7.85 appeared which were attributed to -NH₂, aromatic and -NH protons respectively.

The structure of **3** has been substantiated by its mass spectrum which exhibited peaks at m/z 305 (M⁺) and 307 (M+2) and other peaks appearing at m/z 274, 272, 247, 210, 195, 168, 155, and 59 are in accordance with the fragmentation pattern of **3**. Five different routes were employed to synthesize 2-(8-bromonaphtho[2,1-*b*]furan-2-yl)-1,3,4-oxadiazole derivatives, using hydrazide **3** as an intermediate.

In the first method, the hydrazide **3** was reacted with various aromatic acid chlorides in presence of base, to obtain N-aro-yl-8-bromonaphtho[2,1-*b*]furan-2-carboxyhydrazides **4(a-f)** in moderate yield. The spectral data supported the formation of compounds **4(a-f)**. The IR spectrum of **4d** exhibited absorption bands at 3221 and 1694 cm⁻¹ due to NH and C=O stretching frequencies respectively. ¹H NMR spectrum of **4d** substantiated the assigned structure, showing a multiplet at δ 7.45-8.4 due to 11 aromatic protons and two D₂O exchangeable singlets at δ 9.25 and δ 9.60 due to protons of two NH groups. The IR and ¹H NMR spectral data of these compounds is summarized in Table 3.

The compounds **4(a-f)** underwent ring closure on refluxing with phosphorus oxychloride and furnished 2-(8-bromonaphtho[2,1-*b*]furan-2-yl)-5-aryl-1,3,4-oxadiazoles **5(a-f)**. The structures assigned to **5(a-f)** were evident as their IR spectra showed absence of absorption bands due to two NH and carbonyl frequencies. Similarly ¹H NMR spectrum of **5d** was devoid of singlets at δ 9.25 and 9.60 due to protons due to two NH groups. The ¹³C NMR spectrum of **5d** was recorded to confirm its structure, which showed absence of peak at δ 149.08 due to carbonyl carbon. The mass spectrum of **5d** exhibited peak at m/z 391 corresponding to its molecular weight. The peaks appearing at m/z 374, 312, 214, 197, 181, 166, 146, 119, 103 were in accordance with the fragmentation pattern. The IR and ¹H NMR spectral data of these compounds is summarized in Table 4.

The oxadiazoles **5(a-k)** were also prepared by an alternative method, which involved the conversion of hydrazide **3** into corresponding Schiff bases i.e., N-(arylmethylene)-8-bromonaphtho[2,1-*b*]furan-2-carboxyhydrazides **6(a-k)** obtained by reacting **3** with appropriate aromatic aldehydes bearing electron withdrawing

and electron donating groups. The formation of compounds **6(a-k)** was confirmed by their IR spectra exhibiting absorption bands at 1654 cm^{-1} and 1606 cm^{-1} due to carbonyl and C=N stretching frequencies respectively. In ^1H NMR spectrum of **6a** a singlet at δ 3.87 due to $-\text{OCH}_3$ protons, a multiplet at 7.6-8.5 due to aromatic and $-\text{N}=\text{CH}$ protons and a D_2O exchangeable singlet at δ 9.52 due to $-\text{CONH}$ proton were observed. The structure assigned was substantiated by ^{13}C NMR (DMSO-d_6) spectrum of **6a**, which contained a peak at δ 149.08 due to carbonyl carbon and at δ 129.59 due to $-\text{CH}=\text{N}$ carbon. The peak appearing at δ 55.43 was attributed to methoxy carbon atom. The bunch of peaks of 111.08, 114.37, 116.50, 123.94, 126.10, 126.77, 128.26, 128.47 were assignable to remaining carbon atoms. The same method was employed to yield compounds **6(b-f)** from **3**. The IR and ^1H NMR spectral data of these compounds is summarized in Table 5.

The Schiff bases **6(a-k)** underwent oxidative cyclodehydrogenation to yield oxadiazoles **5(a-k)**. The products formed thus were identical with the oxadiazoles obtained from **4(a-f)** as indicated by superimposable spectra and study of mixed melting points.

The IR and ^1H NMR spectral data of these compounds is summarized in Table 4.

The compounds encompassing naphthofuran, oxadiazole ring systems are known to exhibit wide

spectrum of biological activities. Hence, it was contemplated to evaluate newly synthesized compounds for antimicrobial activities by adopting literature procedure. The compounds **2**, **3**, **4(a-b)**, **5a**, **5d**, **5f**, **5(h-k)**, **6k**, exhibited very good activity against *Staphylococcus pyogens*. The compounds **4a**, **5b**, **5c**, **5e**, **5h**, **5j** and **5k** showed moderate activity against *Staphylococcus aureus*. The compound **4b** possess excellent activity and **2**, **5(b-c)** and **6j** exhibited very good antibacterial activity against *Pseudomonas aeruginosa*. The compounds **3**, and **4f** exhibited very good activity against *Bacillus subtilis*. The compounds **4b**, **5b**, **5(e-f)**, **6a**, **6f**, **6(j-k)** were found to be significantly active against *Bacillus subtilis*. The compound **6e** was the most potent compound, which exhibited excellent activity against *Aspergillum niger*. The compounds **3**, **4b**, **4e**, **5b**, **5e**, **6d** and **6k**, exhibited very good activity against *Aspergillum niger*. The compounds **4b**, and **5f** exhibited very good activity against *Aspergillum flavus*. The compounds **5c** and **6h** exhibited promising activity against *Aspergillum flavus*. The compounds **6g** and **6i** were found to be significantly active against *Candida albicans*. The remaining compounds were found to have moderate or slight active against tested organism and some of the compounds were found to be inactive.

Table 1: Physical and analytical data of newly synthesized compounds

Comp	R	M. P C	Yield (%)	Mol. Formula	Found (Calcd) %		
					C	H	N
2	-	145	94	$\text{C}_{15}\text{H}_{11}\text{O}_3\text{Br}$	56.43 (56.45)	3.45 (3.47)	-
3	-	185	97	$\text{C}_{13}\text{H}_9\text{N}_2\text{O}_2\text{Br}$	51.00 (51.17)	2.50 (2.97)	9.15 (9.18)
4a	4- OCH_3 C_6H_4	155	71	$\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_4\text{Br}$	57.31 (57.42)	3.40 (3.44)	6.31 (6.38)
4b	4-Cl C_6H_4	195	67	$\text{C}_{20}\text{H}_{12}\text{N}_2\text{O}_3\text{BrCl}$	54.11 (54.14)	2.71 (2.73)	6.29 (6.31)
4c	4- NO_2 C_6H_4	230	67	$\text{C}_{20}\text{H}_{12}\text{N}_3\text{O}_5\text{Br}$	52.80 (52.88)	2.61 (2.66)	9.20 (9.25)
4d	C_6H_5	170	67	$\text{C}_{20}\text{H}_{13}\text{N}_2\text{O}_3\text{Br}$	58.65 (58.70)	3.158 (3.20)	6.72 (6.85)
4e	2-Cl C_6H_4	115	86	$\text{C}_{20}\text{H}_{12}\text{N}_2\text{O}_3\text{BrCl}$	54.10 (54.14)	2.70 (2.73)	6.25 (6.31)
4f	3- NO_2 C_6H_4	110	93	$\text{C}_{20}\text{H}_{12}\text{N}_3\text{O}_5\text{Br}$	52.78 (52.88)	2.65 (2.66)	9.15 (9.25)
5a	4- OCH_3 C_6H_4	170	81	$\text{C}_{21}\text{H}_{13}\text{N}_2\text{O}_3\text{Br}$	59.53 (59.59)	3.50 (3.57)	6.59 (6.62)
5b	4-Cl C_6H_4	245	71	$\text{C}_{20}\text{H}_{10}\text{N}_2\text{O}_2\text{BrCl}$	56.00 (56.17)	2.65 (2.83)	6.45 (6.55)
5c	4- NO_2 C_6H_4	260	92	$\text{C}_{20}\text{H}_{10}\text{N}_3\text{O}_4\text{Br}$	54.75 (54.81)	2.66 (2.76)	9.49 (9.59)
5d	C_6H_5	265	76	$\text{C}_{20}\text{H}_{11}\text{N}_2\text{O}_2\text{Br}$	61.00 (61.09)	3.28 (3.31)	7.10 (7.12)
5e	2-Cl C_6H_4	245	55	$\text{C}_{20}\text{H}_{12}\text{N}_2\text{O}_2\text{BrCl}$	56.08	2.75	6.30

					(56.17)	(2.83)	(6.55)
5f	3-NO ₂ C ₆ H ₄	265	96	C ₂₀ H ₁₂ N ₂ O ₄ Br	54.76 (54.81)	2.65 (2.76)	9.46 (9.59)
5g	C ₁₀ H ₇ O	245	62	C ₂₄ H ₁₅ N ₂ O ₃ Br	62.56 (62.76)	3.25 (3.29)	6.05 (6.10)
5h	CH=CH C ₆ H ₅	245	69	C ₂₂ H ₁₅ N ₂ O ₂ Br	63.00 (63.02)	3.59 (3.61)	8.62 (8.68)
5i	C ₄ H ₃ O	235	63	C ₁₈ H ₁₁ N ₂ O ₃ Br	56.32 (56.42)	2.15 (2.89)	7.22 (7.31)
5j	4-OH C ₆ H ₄	285	69	C ₂₀ H ₁₃ N ₂ O ₃ Br	58.65 (58.70)	3.16 (3.20)	6.75 (6.85)
5k	4-OCH ₃ 3-OH C ₆ H ₃	280	74	C ₂₁ H ₁₅ N ₂ O ₄ Br	57.39 (57.42)	3.39 (3.44)	6.30 (6.38)
6a	4-OCH ₃ C ₆ H ₄	170	81	C ₂₁ H ₁₅ N ₂ O ₃ Br	59.63 (59.59)	3.50 (3.57)	6.759 (6.62)
6b	4-Cl C ₆ H ₄	245	71	C ₂₀ H ₁₂ N ₂ O ₂ BrCl	56.00 (56.17)	2.65 (2.83)	6.45 (6.55)
6c	4-NO ₂ C ₆ H ₄	260	92	C ₂₀ H ₁₂ N ₃ O ₄ Br	54.75 (54.81)	2.66 (2.76)	9.49 (9.59)
6d	C ₆ H ₅	265	76	C ₂₀ H ₁₃ N ₂ O ₂ Br	61.22 (61.09)	3.28 (3.31)	7.10 (7.12)
6e	2-Cl C ₆ H ₄	245	55	C ₂₀ H ₁₂ N ₂ O ₂ BrCl	56.08 (56.17)	2.75 (2.83)	6.30 (6.55)
6f	3-NO ₂ C ₆ H ₄	265	96	C ₂₀ H ₁₂ N ₃ O ₄ Br	54.76 (54.81)	2.65 (2.76)	9.46 (9.59)
6g	C ₁₀ H ₇ O	245	62	C ₂₄ H ₁₅ N ₂ O ₃ Br	62.56 (62.76)	3.25 (3.29)	6.05 (6.10)
6h	CH=CH C ₆ H ₅	245	69	C ₂₂ H ₁₅ N ₂ O ₂ Br	63.00 (63.02)	3.59 (3.61)	8.62 (6.68)
6i	C ₄ H ₃ O	235	63	C ₁₈ H ₁₁ N ₂ O ₃ Br	56.32 (56.42)	2.15 (2.89)	7.22 (7.31)
6j	4-OH C ₆ H ₄	285	69	C ₂₀ H ₁₃ N ₂ O ₃ Br	58.65 (58.70)	3.16 (3.20)	6.75 (6.85)
6k	4-OCH ₃ 3-OH C ₆ H ₃	280	74	C ₂₁ H ₁₅ N ₂ O ₄ Br	57.39 (57.42)	3.39 (3.44)	6.30 (6.38)


Table 2: Antimicrobial activity data of prepared compounds

Comp	R	Zone of inhibition in mm						
		Antibacterial activity				Antifungal activity		
		<i>B. subtilis</i>	<i>P. aeruginosa</i>	<i>S. pyogenes</i>	<i>S. aureus</i>	<i>A. niger</i>	<i>C. albicans</i>	<i>A. flavus</i>
2	-	18	23	22	15	14	15	12
3	-	25	15	18	17	18	12	16
4a	4-OCH ₃ C ₆ H ₄	18	16	19	18	14	17	17
4b	4-Cl C ₆ H ₄	23	25	22	17	19	15	22
4c	4-NO ₂ C ₆ H ₄	18	18	10	15	7	16	-
4d	C ₆ H ₅	10	17	13	10	14	12	-
4e	2-Cl C ₆ H ₄	13	15	13	12	20	11	-
4f	3-NO ₂ C ₆ H ₄	25	12	16	12	7	12	13
5a	4-OCH ₃ -C ₆ H ₄	19	18	18	17	12	18	16
5b	4-Cl- C ₆ H ₄	20	24	14	19	19	16	13
5c	4-NO ₂ - C ₆ H ₄	17	20	12	18	14	11	16
5d	- C ₆ H ₅	13	15	22	17	8	11	-
5e	2-Cl- C ₆ H ₄	20	19	16	18	19	15	14
5f	3-NO ₂ - C ₆ H ₄	20	13	21	17	14	11	22
5g	C ₁₀ H ₇ O	17	16	15	17	11	17	13
5h	-CH=CH-C ₆ H ₅	18	17	18	18	12	16	13
5i	Furfural	16	16	19	17	13	18	13
5j	4-OH- C ₆ H ₄	17	15	18	18	11	20	14
5k	3-OCH ₃ -4-OH C ₆ H ₃	19	16	20	19	14	20	15
6a	4-OCH ₃ -C ₆ H ₄	20	16	-	-	11	11	-
6b	4-Cl- C ₆ H ₄	17	10	-	-	13	12	-
6c	4-NO ₂ - C ₆ H ₄	16	16	-	-	8	12	11

6d	- C ₆ H ₅	17	18	-	-	18	10	9
6e	2-Cl- C ₆ H ₄	18	11	-	-	22	10	16
6f	3-NO ₂ - C ₆ H ₄	20	-	-	-	-	11	-
6g	C ₁₀ H ₇ O	15	15	-	-	-	22	13
6h	-CH=CH- C ₆ H ₅	10	15	-	-	14	10	19
6i	Furfural	15	18	-	-	11	21	13
6j	4-OH- C ₆ H ₄	20	23	-	10	14	13	8
6k	3-OCH ₃ -4-OH C ₆ H ₃	20	-	18	17	19	18	-
(Standard) Chloamphenicol		35	25	24	26	-	-	-
Flucanazole		-	-	-	-	22	24	26

Zone of inhibition in millimeters.

Scheme-1



R	R
a 4OCH ₃ -C ₆ H ₄	f 3NO ₂ C ₆ H ₄
b 4Cl C ₆ H ₄	g Naphthaldehyde
c 4NO ₂ C ₆ H ₄	h CH=CH C ₆ H ₅
d C ₆ H ₅	i Furfural
e 2Cl C ₆ H ₄	j 4OH C ₆ H ₄
	k 3OCH ₃ 4OH C ₆ H ₃

Table-3: IR and ¹H NMR Spectral data of 8-Bromonaphtho [2,1-b]furan-2- carbohydrazide (4a-f)

Comp.	R	IR (KBr)cm ⁻¹		¹ H NMR in ppm
		NH	C=O	
4a	4-OCH ₃ -C ₆ H ₄	3200	1657	δ 3.87 (s, 3H, OCH ₃), δ 7.6-8.5 (m, 10H, ArH) δ 9.52, 9.48 (s, 2H, 2NH)
4b	4-Cl-C ₆ H ₄	3210	1625	δ 7.5-8.1 (m, 10H, ArH), δ 9.55, 9.30 (s, 2H, 2NH)
4c	4-NO ₂ -C ₆ H ₄	3217	1684	δ 7.55-8.1 (m, 10H, ArH), δ 11.02, 10.99 (s, 2H, 2NH)
4d	C ₆ H ₅	3217	1687	δ 7.45-8.4 (m, 11H, ArH), δ 9.6, 9.25 (s, 2H, 2NH)
4e	2-Cl-C ₆ H ₄	3208	1680	δ 7.6-8.2 (m, 10H, ArH), δ 9.51, 9.28 (s, 2H, 2NH)
4f	3-NO ₂ -C ₆ H ₄	3214	1685	δ 7.55-8.1 (m, 10H, ArH), δ 11.00, 10.94 (s, 2H, NH)

Table - 4: IR and ¹H NMR Spectral data of 2-(8-bromonaphtho [2,1-b]furan-2-yl)-5-aryl-1,3,4-oxadizoles (5a-f)

Comp.	R	IR (KBr) cm ⁻¹		¹ H NMR (CDCl ₃)
		C=N		
5a	4-OCH ₃ -C ₆ H ₄	1608		δ 3.9(s, 3H, OCH ₃), δ 7.12-8.4 (m, 10H, ArH)
5b	4-Cl-C ₆ H ₄	1606		δ 7.3-8.3 (m, 10H, ArH)
5c	4-NO ₂ -C ₆ H ₄	1625		δ 7.4-8.6 (m, 10H, ArH)
5d	-C ₆ H ₅	1606		7.5-8.5 (m, 11H, ArH)
5e	2-Cl-C ₆ H ₄	1610		7.2-8.7 (m, 11H, ArH)
5f	3-NO ₂ -C ₆ H ₄	1624		δ 7.2-8.4 (m, 10H, ArH)

Table-5: IR and ¹H NMR Spectral data of N-[(aryl)methylene]-8-bromonaphtho[2,1-b]furan-2-carbohydrazides [Schiff's base] (6a-k)

Comp.	Ar	IR (KBr) cm ⁻¹		¹ H NMR in ppm
		C=N	C=O	
6a	4-OCH ₃ -C ₆ H ₄	1606	1655	δ 3.87 (s, 3H, OCH ₃), δ 6.9-8.5 (m, 10H, ArH & N=CH) δ 9.52 (s, 1H, CONH)
6b	4-Cl-C ₆ H ₄	1594	1648	δ 7.2-8.6 (m, 11H, ArH & N=CH), δ 9.7 (s, 1H, CONH)
6c	4-NO ₂ -C ₆ H ₄	1598	1675	δ 7.3-8.61 (m, 11H, ArH & N=CH), δ 9.23 (s, 1H, CONH)
6d	-C ₆ H ₅	1603	1647	δ 7.4-8.5 (m, 11H, ArH & N=CH), δ 9.68 (s, 1H, CONH)
6e	2-Cl-C ₆ H ₄	1610	1680	δ 7.4-8.5 (m, 11H, ArH & N=CH), δ 9.4 (s, 1H, CONH)
6f	3-NO ₂ -C ₆ H ₄	1596	1670	δ 7.3-8.61 (m, 11H, ArH & N=CH), δ 9.22 (s, 1H, CONH)
6g	C ₁₀ H ₇ O	1609	1685	δ 4.18 (b, 1H, OH), δ 7.1-8.55(m, 13H, ArH & N=CH), δ 10.1 (s, 1H, CONH)
6h	-CH=CH-C ₆ H ₅	1600	1668	δ 7.4-8.5 (m, 14H, ArH & N=CH, CH=CH), δ 9.2 (s, 1H, CONH)
6i	Furfural	1609	1685	δ 7.1-8.2 (m, 10H, ArH & N=CH), δ 8.6 (s, 1H, NCH), δ 9.8 (s, 1H, CONH)
6j	4-OH-C ₆ H ₄	1620	1684	δ 4.25 (b, 1H, OH), δ 7.2-8.6 (m, 11H, ArH & N=CH), δ 9.6 (s, 1H, CONH)
6k	3-OCH ₃ -4-OH C ₆ H ₃	1615	1660	δ 3.82 (s, 3H, OCH ₃), δ 4.22 (b, 1H, OH), δ 7.6-8.5 (m, 10H, ArH & N=CH) δ 9.54 (s, 1H, CONH)

CONCLUSION

The synthesis of novel biheterocycles comprising naphtho[2,1-*b*]furan and 1,3,4-oxadiazoles ring systems, containing bromine atom at position 8 of naphthofuran nucleus and various substituents at position 5 of 1,3,4-oxadiazole nucleus has been carried out successfully. Overall conclusion is that introduction of bromine atom in position 8 of naphthofuran ring enhanced antimicrobial to certain extent as compared with the compounds without bromine atom in that position^{16, 27}. In general, electron donating groups at position 5 of oxadiazole nucleus were found to exhibit more antimicrobial activity in comparison with the compound containing electron withdrawing groups in the same position.

ACKNOWLEDGEMENTS

The authors are thankful to Head, SAIF, CDRI, Lucknow and IISc, Bangalore for providing the spectral analysis. One of the authors (DR) is grateful to UGC, New Delhi for awarding teacher fellowship.

REFERENCES

1. Raghavendra R, Mahadevan KM, Satyanarayan ND, Bhanuprakash V, Venkatesan G and Yogisharadhya R. Analgesic, Antibacterial and Antiviral Activities of 2-(5-Alkyl-1,3,4-oxadiazol-2-yl)-3H-benzofuro[3,2-c]chromen-3-ones. *Indian J Pharm Sci.* 2012;74(4):367-371.
2. Thriveni KS, Padmashali Basavaraj, Siddesh MB, Sandeep C, Nagesh HK and Mallikarjun SM. Synthesis and Antimicrobial Screening of Naphthofuran-1, 3, 4-Oxadiazole linked piperazine. *Universal J Pharmacy.* 2013;2(4):129-134.
3. Bakht MA, Shahar Yar M, Abdel-Hamid SG, Al Qasoumi SI and Samad A. Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. *Eur J Med Chem.* 2010;45:5862-5869.
4. Mayekar AN, Yathirajan HS, Narayana B, Sarojini BK and Suchetha Kumari N. Synthesis and Antimicrobial Studies on New Substituted 1,3,4-Oxadiazole Derivatives Bearing 6-Bromonaphthalene Moiety. *Int J Chem.* 2010;2:38-54.
5. Sanjeevkumar Giri and Basavaraja KM. Synthesis of 3-methoxy-2-(1,3,4-oxadiazolyl),1,3,4-thiadiazolyl and 1,2,4-triazolyl)naphtho[2,1-*b*]furans of biological interest. *J Chem and Pharma Res.* 2012;4(5):2643-2648.
6. Jumat Salimon, Nadia Salih, Ayad Hameed, Emad Yousif. Synthesis, characterization and antimicrobial evaluation of some 1, 3, 4-oxadiazole derivatives. *Int J Pharm Tech Res.* 2011;3(2):1097-1102.
7. Shetgiri NP and Nayak BK. Synthesis, antimicrobial and antiinflammatory activities of 1, 3, 4-oxadiazoles linked to naphtho[2, 1-*b*] furan. *Indian J Chem.* 2005;44B:1267-1271.
8. Pramod Kumar Sharma, Poonam Singh, Jitendra Kumar Sharma, Anshu Upadhyay and Nitin Kumar. Synthesis and evaluation of substituted diphenyl-1,3,4-oxadiazole derivatives for central nervous system depressant activity. *Organic and Medicinal Chemistry Letters.* 2012;2(8):1-10.
9. Arvind Kumar Singh, Parthasarthy R and Lohani M. Synthesis, characterization and anti-inflammatory activity of some 1, 3, 4-oxadiazole derivatives. *J Chem and Pharma Res.* 2012;4(1):779-782.
10. Bhargab N, Shamanna M, Janardhan S, Satyendra D, Apurba T, Bhargab JS, Biplab Kumar D and Rama Kanta S. Syntheses and Characterization of some Novel Oxadiazoles for in-vitro Anti-inflammatory activity. *Int J Res in Pharma and Chem.* 2012;2(3):594-602.
11. Pinaki S, Deepakkumar D, Veerendra CY, Murgesh K, Rajalingam D and Maity TK. Evaluation of anticancer activity of some 1, 3, 4-oxadiazole derivatives. *Indian J Chem.* 2008;47(B):460-462.
12. Holla BS, Gonsalves R and Shenoy S. Synthesis and antibacterial studies of a new series of 1,2-bis(1,3,4-oxadiazole-2-yl) ethanes and 1,2-bis(4-amino-1,2,4-triazole-3-yl) ethanes. *Eur J Med Chem.* 2000;35:267-271.
13. Chen HLiZ and Han Y. Synthesis and Fungicidal Activity against *Rhizoctonia solani* of 2-Alkyl(Alkylthio)-5-pyrazolyl-1,3,4-oxadiazoles (Thiodiazoles). *J Agric Food Chem.* 2000;48:5312-5315.
14. Ashour FA, El-Hawash SAM, Mahran MA et al. Synthesis, antibacterial and anti-fungal activity of some new 1,3,4-oxadiazoles and 2-substituted amino-

- 1,3,4-oxadiazoles containing benzimidazole moiety. Bull Pharm Sci Assiut Univ. 1994;17:17-21.
15. Mahadevan KM and Vaidya VP. Synthesis and Pharmacological Evaluation of Some Potent Naphtho [2,1-*b*] furo-Pyrazolyl Oxadiazolyl and Coumaryl Derivatives. Indian J Pharm Sci. 2003;65:128-134.
 16. Vagdevi HM and Vaidya VP. Studies in naphthofurans: Part III-Synthesis of 2-substituted naphtha[2,1]furans, 2-(2'-aryl-3'-acetyl-1',3'4'-oxadiazolyl) amino naphtha[2,1-*b*]furans and their biological activities. India J Heterocyclic Chem. 2001;10:253-260.
 17. Venegas W, Lasne C, Lowy R, Buisson JP and Chouroulinkov L. Naphthofurans induced chromosomal aberrations detected in metaphase, anaphase and telophase V79 Chinese hamster cells. Mutat Res. 1985;157(1):53-62.
 18. Shet Prakash M, VP Vaidya, Mahadevan KM, Shivananda and Vijayakumar GR. Synthesis, Characterization and antimicrobial studies and novel N-substituted naphthofuran carbaxamides. J Pharma Sci and Technology. 2011;3(10):996-1002.
 19. Monte AP, Lewicka DM, Lewis MM, Mailman RB, Wainscott DB, Nelson DL and Nichols DE. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. J Med Chem. 1998;41(12):2134-2145.
 20. Mahadevan KM, Basavaraj Padmashali and Vaidya VP. Studies in naphthofurans: Part V-Synthesis of 2-aryl-1,2,3,4-tetrahydropyrido)naphtha[2,1-*b*]furan)-4-ones and their biological activity. Indian J Heterocyclic Chem. 2001;11:15-20.
 21. Ramesh D, Chandrashekhar C and Vaidya VP. Synthesis of novel naphtho[2,1-*b*]furo[3,2-*b*]pyridine derivatives as potential antimicrobial agents. Indian J Chem. 2008;47B:753-758.
 22. Rajashekhar H, Ramesh D, Chandrashekhar C, Mahadevan KM and Vaidya VP. Synthesis of 2-(3-Nitronaphtho[2,1-*b*]furan-2-yl)-5-substituted-1,2,4-oxadiazole and their biological activities. Indian J Heterocyclic Chem. 2007;16:353-357.
 23. Vagdevi HM, Latha KP, Vaidya VP, Vijayakumar ML and Pai KSR. Synthesis and pharmacological screening of some novel naphtho [2,1-*b*] furo pyrazolines, isoxazoles and isoxazolines, Indian J Pharm Sci. 2001;63:286-291.
 24. Mahadevan KM, Basavaraj KM, Prathima Mathias DA and Vaidya VP. Synthesis of novel naphtho[2,1-*b*]furo pyrazolyl, isoxazolyl and pyridyl derivatives as potential antimicrobial agents. Indian J Chem. 2005;44B:789-793.
 25. Ramesh D, Chandrashekhar C and Vaidya VP. Synthesis, analgesic, antiinflammatory and antimicrobial activities of naphtho [2,1-*b*] furan incorporated substituted pyrimidines. Indian J Heterocyclic Chem. 2006;15:319-322.
 26. Ravindra KC, Vaidya VP, Chandrashekhar C and Vagdevi HM. Synthesis of substituted biheterocycles of triazole, thiadiazole and oxadiazole involving naphtho[2,1-*b*]furan and their antimicrobial activity. Indian J Heterocyclic Chem. 2006;15:283-286.
 27. Mahadevan KM and Vaidya VP. Synthesis and Pharmacological Evaluation of Some Potent Naphtho [2,1-*b*] furo-Pyrazolyl Oxadiazolyl and Coumaryl Derivatives. Indian J Pharm Sci. 2003;65(2):128-132.
 28. Indian Pharmacopoeia. Antimicrobial. Controller of Publications, Delhi. 1996;2:100-106.